STK32B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4135600	0.78	2/20
Brivanib (SCHEMBL1227111)	1.00	1/20
Brivanib (SCHEMBL1227112)	1.00	1/20
Brivanib (SCHEMBL1227589)	1.00	1/20
SCHEMBL1990603	1.00	1/20
Brivanib (SCHEMBL29354510)	1.00	1/20
SCHEMBL14111448	0.84	1/20
SCHEMBL1226392	0.84	1/20
SCHEMBL3450913	0.84	1/20
SCHEMBL3451591	0.84	1/20
SCHEMBL1227534	0.83	1/20
SCHEMBL6471061	0.83	1/20
SCHEMBL1226332	0.82	1/20
SCHEMBL1227523	0.82	1/20
SCHEMBL1227542	0.82	1/20
SCHEMBL11965798	0.82	1/20
SCHEMBL11965800	0.82	1/20
SCHEMBL1226301	0.81	1/20
SCHEMBL1226302	0.81	1/20
SCHEMBL1227577	0.79	1/20

Clinical trials — most relevant to STK32B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)	PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	PHASE2	ACTIVE_NOT_RECRUITING
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Exercise in Type 1 Diabetes Mellitus	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Biomarker Analysis of Gastrointestinal Cancer	nan	UNKNOWN
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment	nan	UNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a STK32B binder may also engage these)

Protein	Name	Similarity
Q9JJX8	—	1.000	Q9JJX8 →
STK32A	Serine/threonine-protein kinase 32A	1.000	landscape →
STK32C	Serine/threonine-protein kinase 32C	0.994	landscape →
RPS6KB1	Ribosomal protein S6 kinase beta-1	0.993	landscape →
Q6TJY3	—	0.992	Q6TJY3 →
Q8BSK8	—	0.992	Q8BSK8 →
Q8BGW6	—	0.991	Q8BGW6 →
Q62074	—	0.991	Q62074 →
Q6PFQ0	—	0.990	Q6PFQ0 →
O19111	—	0.990	O19111 →
Q39030	—	0.990	Q39030 →
Q8C050	—	0.990	Q8C050 →
Q9NBK5	—	0.989	Q9NBK5 →
Q02111	—	0.989	Q02111 →
Q91VJ4	—	0.989	Q91VJ4 →
Q02956	—	0.989	Q02956 →
F1M7Y5	—	0.989	F1M7Y5 →
Q09136	—	0.989	Q09136 →
Q5R4K9	—	0.988	Q5R4K9 →
Q90XF2	—	0.988	Q90XF2 →
Q5R8M1	—	0.988	Q5R8M1 →
Q8BHI9	—	0.988	Q8BHI9 →
Q2LZZ7	—	0.988	Q2LZZ7 →
Q12706	—	0.988	Q12706 →
PRKCZ	Protein kinase C zeta type	0.987	landscape →
STK38	Serine/threonine-protein kinase 38	0.987	landscape →
P67998	—	0.987	P67998 →
PRKCQ	Protein kinase C theta type	0.987	landscape →
P09217	—	0.987	P09217 →
Q91VB2	—	0.986	Q91VB2 →